Diversified Trust Co. Invests $621,000 in argenex SE $ARGX

Diversified Trust Co. bought a new stake in shares of argenex SE (NASDAQ:ARGX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 738 shares of the company’s stock, valued at approximately $621,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Ameriflex Group Inc. purchased a new position in argenex during the third quarter worth approximately $32,000. Sunbelt Securities Inc. purchased a new stake in shares of argenex in the third quarter valued at approximately $36,000. Aventura Private Wealth LLC purchased a new stake in shares of argenex in the fourth quarter valued at approximately $38,000. Bessemer Group Inc. raised its stake in shares of argenex by 276.5% during the 3rd quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock worth $47,000 after buying an additional 47 shares during the period. Finally, MAI Capital Management raised its stake in shares of argenex by 866.7% during the 2nd quarter. MAI Capital Management now owns 87 shares of the company’s stock worth $48,000 after buying an additional 78 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Trading Down 0.2%

NASDAQ:ARGX opened at $691.40 on Friday. The company’s 50-day moving average price is $781.05 and its 200-day moving average price is $813.59. The company has a market cap of $42.78 billion, a P/E ratio of 35.42, a P/E/G ratio of 1.14 and a beta of 0.38. argenex SE has a twelve month low of $510.05 and a twelve month high of $934.62.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Saturday, February 14th. The company reported $8.02 earnings per share (EPS) for the quarter. argenex had a net margin of 30.42% and a return on equity of 38.51%. On average, analysts expect that argenex SE will post 3.13 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Citizens Jmp lifted their price target on shares of argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a research note on Friday, February 27th. Zacks Research upgraded shares of argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. Wells Fargo & Company decreased their price objective on shares of argenex from $1,317.00 to $1,247.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Morgan Stanley lifted their target price on shares of argenex from $1,070.00 to $1,110.00 and gave the company an “overweight” rating in a research report on Thursday, December 4th. Finally, Robert W. Baird boosted their target price on shares of argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a research note on Friday, February 27th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, argenex presently has a consensus rating of “Moderate Buy” and a consensus target price of $999.22.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.